Regulatory control of inflammatory cytokine production by a linear ubiquitin-binding protein
线性泛素结合蛋白对炎症细胞因子产生的调节控制
基本信息
- 批准号:10337076
- 负责人:
- 金额:$ 7.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-02-02 至 2022-07-29
- 项目状态:已结题
- 来源:
- 关键词:AcademiaAdvisory CommitteesAffectAnti-Inflammatory AgentsApoptosisApoptoticAutoimmune DiseasesAutoimmunityBindingBinding ProteinsBiological ProcessBiological Response ModifiersBiologyCASP8 geneCRISPR/Cas technologyCSF3 geneCell DeathChronic DiseaseClinical PathologyClinics and HospitalsCommunicable DiseasesComplexCore FacilityDendritic CellsDiseaseDoctor of MedicineDoctor of PhilosophyEnvironmentEquilibriumFive-Year PlansGene DeletionGenesGeneticGenetic PolymorphismHealthHomeostasisHumanIRAK1 geneIRAK4 geneImmuneImmune System DiseasesImmunityImmunodeficiency and CancerImmunologic ReceptorsIn VitroIndustryInflammationInflammatoryInflammatory ResponseInflammatory Response PathwayInnate Immune ResponseInnate Immune SystemInstitutionInterleukin-1 ReceptorsInterleukin-6JointsKnock-inKnockout MiceLigandsLightLinkMAP Kinase GeneMediatingMentorsMentorshipModelingMolecularMusNF-kappa BNatural ImmunityOutputPathway interactionsPattern recognition receptorPhysiciansPoint MutationPolyubiquitinPost-Translational Protein ProcessingProductionProteinsRIPK1 geneReceptor SignalingRegulationResearchResearch PersonnelResearch ProposalsResidenciesResistanceResourcesRibonucleasesRoleScientistSeriesSeveritiesSignal PathwaySignal TransductionSyndromeSystemTLR1 geneTLR3 geneTLR4 geneTLR7 geneTNF geneTNFRSF5 geneTestingTherapeuticTimeToll-like receptorsTrainingTumor Necrosis Factor ReceptorUbiquitinUbiquitinationUniversitiesautoinflammatorycareercareer developmentcell typecytokinedisease-causing mutationexperimental studyin vivoinhibitorlaboratory facilitymacrophagemedical schoolsmouse modelmutantmutant mouse modelnovelnovel strategiesprogramsreceptorrecruitresponse
项目摘要
PROJECT SUMMARY/ABSTRACT
This proposal outlines a five-year plan for the PI, Dr. Alexander Gitlin, to prepare him for an independent
academic career as a physician-scientist. Dr. Gitlin received his M.D./Ph.D. degrees from the Weill
Cornell/Rockefeller/Sloan-Kettering Tri-Institutional M.D.-Ph.D. program and is currently completing residency in
Clinical Pathology at Stanford Hospital and Clinics. During residency, Dr. Gitlin developed a jointly mentored
research program, co-advised by Drs. Bali Pulendran (Stanford University) and Vishva Dixit (Genentech, Inc.).
Drs. Pulendran and Dixit are longtime colleagues and collaborators with highly complementary expertise. Dr.
Pulendran is an expert in toll-like receptors, innate immunity, and dendritic cells; Dr. Dixit is an expert on
inflammatory signaling, cell death, and ubiquitin biology. Both Drs. Pulendran and Dixit have served as mentors
to numerous trainees, many of whom have become leading investigators in academia or industry. This joint
mentorship program provides Dr. Gitlin with full access to the combined resources and expertise present at two
neighboring, world-class research institutions, Stanford University and Genentech, which will provide
outstanding environments for Dr. Gitlin to develop his own independent scientific career. In addition, Dr. Gitlin
has assembled a K08 advisory committee composed of senior investigators whose scientific expertise and
mentorship will greatly aid Dr. Gitlin’s career development. They include Drs. Stephen Galli, Denise Monack,
Scott Boyd, and Andrey Shaw. Furthermore, Dr. Gitlin will have access to coursework, retreats, seminars and
resources through Stanford University’s School of Medicine, The Stanford Office of Postdoctoral Affairs, and the
Genentech Postdoctoral Program. Finally, the scientific resources available to Dr. Gitlin comprise the
Pulendran/Dixit laboratories and core facilities at both Stanford University and Genentech, representing an
extraordinary set of scientific resources. The research proposal detailed herein seeks to uncover the molecular
mechanisms by which linear ubiquitin controls the magnitude of the innate immune response. Dysregulated
inflammatory and cytokine responses are fundamental features of multiple chronic diseases, including
autoimmunity, autoinflammatory syndromes, infectious diseases, immunodeficiencies and cancer. Yet, many of
the complex signaling pathways that regulate inflammatory signaling are still being unraveled at a mechanistic
level. During Dr. Gitlin’s short time as a co-mentee of Drs. Dixit and Pulendran, he has discovered that the
NEDD4-binding protein 1 (N4BP1), a linear ubiquitin-binding protein, is a novel regulator of toll-like receptor
(TLR) responses. In Aim 1, we will test the hypothesis that N4BP1 differentially regulates inflammatory cytokine
production downstream of TLR signaling. In Aim 2, we will dissect the mechanistic basis of N4BP1 activity by
inactivating its independent functional motifs. We anticipate these studies will elucidate a novel pathway by which
a previously enigmatic linear ubiquitin-binding protein selectively controls the cytokine output of TLRs. These
studies provide an excellent platform for Dr. Gitlin to complete his training and launch his independent career.
项目摘要/摘要
该提案概述了PI的五年计划,亚历山大吉特林博士,为他独立做准备。
作为一名物理学家和科学家的学术生涯。Gitlin博士获得了医学博士学位/博士从韦尔度
康奈尔/洛克菲勒/斯隆-凯特琳三机构医学博士-博士计划,目前正在完成居住在
斯坦福大学医院临床病理学。在住院期间,Gitlin博士开发了一种联合指导的
Bali Pulendran博士(斯坦福大学)和Vishva Diplomat博士(Genentech,Inc.)共同担任顾问。
Drs. Pulendran和Diplomat是长期的同事和合作者,具有高度互补的专业知识。博士
Pulendran博士是Toll样受体、先天免疫和树突细胞方面的专家;
炎症信号传导、细胞死亡和泛素生物学。Pulendran博士和Diplomat博士都曾担任过导师
许多受训人员,其中许多人已成为学术界或工业界的主要调查人员。这一联合
导师计划为Gitlin博士提供了充分的资源和专业知识,目前在两个
邻近的世界级研究机构,斯坦福大学和基因泰克,这将提供
Gitlin博士发展自己独立的科学事业的良好环境。此外,Gitlin博士
已经组建了一个K 08咨询委员会,由高级研究人员组成,他们的科学专长和
导师制将极大地帮助吉特林博士的职业发展。他们包括斯蒂芬·加利博士,丹尼斯·莫纳克,
斯科特·博伊德和安德烈·肖此外,吉特林博士将有机会参加课程,务虚会,研讨会和
通过斯坦福大学医学院,斯坦福大学博士后事务办公室和
Genentech博士后项目。最后,Gitlin博士可用的科学资源包括:
Pulendran/Diplomat实验室和斯坦福大学和基因泰克的核心设施,代表了
非凡的科学资源。本文详细介绍的研究提案旨在揭示分子
线性泛素控制先天免疫应答的大小的机制。失调
炎症和细胞因子反应是多种慢性疾病的基本特征,包括
自身免疫、自身炎性综合征、感染性疾病、免疫缺陷和癌症。然而,许多
调节炎症信号的复杂信号传导途径仍在以一种机制被解开,
水平在吉特林博士作为Diplomat博士和Pulendran博士的共同指导者的短暂时间内,他发现,
NEDD 4结合蛋白1(N4 BP 1)是一种线性泛素结合蛋白,是Toll样受体的新型调节因子
(TLR)应答在目标1中,我们将检验N4 BP 1差异调节炎性细胞因子的假设
TLR信号传导的下游生产。在目标2中,我们将通过以下方式剖析N4 BP 1活性的机制基础:
使其独立的功能基序失活。我们预计这些研究将阐明一种新的途径,
一种以前神秘的线性泛素结合蛋白选择性地控制TLR的细胞因子输出。这些
研究为Gitlin博士完成培训并开始独立职业生涯提供了一个很好的平台。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alexander Gitlin其他文献
Alexander Gitlin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alexander Gitlin', 18)}}的其他基金
Regulation of Proinflammatory Cytokine Responses by a Caspase-8-N4BP1 Axis
Caspase-8-N4BP1 轴对促炎细胞因子反应的调节
- 批准号:
10704065 - 财政年份:2022
- 资助金额:
$ 7.69万 - 项目类别:
Regulatory control of inflammatory cytokine production by a linear ubiquitin-binding protein
线性泛素结合蛋白对炎症细胞因子产生的调节控制
- 批准号:
10674329 - 财政年份:2021
- 资助金额:
$ 7.69万 - 项目类别:
Molecular Regulation of Germinal Center B Lymphocytes
生发中心 B 淋巴细胞的分子调控
- 批准号:
8649227 - 财政年份:2014
- 资助金额:
$ 7.69万 - 项目类别:
相似海外基金
Toward a Political Theory of Bioethics: Participation, Representation, and Deliberation on Federal Bioethics Advisory Committees
迈向生命伦理学的政治理论:联邦生命伦理学咨询委员会的参与、代表和审议
- 批准号:
0451289 - 财政年份:2005
- 资助金额:
$ 7.69万 - 项目类别:
Standard Grant